Boston Scientific: Undervalued Ahead of Strong Q4 Results, 2026 Outlook, and PEN Acquisition Catalyst
I'm PortAI, I can summarize articles.
TD Cowen analyst Josh Jennings maintains a Buy rating on Boston Scientific (BSX), citing unjustified recent share weakness. He anticipates strong Q4 results, with revenue and earnings likely to meet or exceed expectations. Jennings downplays concerns about a slowdown in electrophysiology procedures and expects a positive 2026 outlook to bolster investor confidence. He believes the upcoming PEN acquisition will enhance sentiment as its strategic benefits become clearer. Barclays also supports BSX with a Buy rating and a $136 price target, reinforcing Jennings' view that the stock is undervalued.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments